Type 2 Diabetic Patients
Conditions
Brief summary
This is a randomized, placebo-controlled, multiple dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR0534. The study will be conducted with dose of 5 mg, 10mg and 25 mg. Chinese Type 2 Diabetic patients will be randomized in each cohort to receive the study drug or placebo.
Interventions
DRUGSHR0534
DRUGPlacebo
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes diagnosed for more than 3 months; * HbA1c between ≥7.0 and ≤10.5% for naive patients, or ≥6.5 and ≤9.5% for patients treated with single oral drug, with FPG ≤13.9 mmol/L at randomization; * Body Mass Index (BMI) between 18 and 40 kg/m\^2 (inclusive) with a total body weight of at least 50 kg; * Agree to stop any other drugs for diabetes during washout and study period; * Serum C peptide concentration ≥0.8ng/mL at randomization.
Exclusion criteria
* Participated any drug clinical trials within 3 months or ≥3 times during the last year, or had blood donation/loss≥400mL or as Blood recipient within 3 months before randomization; * History use of Insulin within 6 months; * Drug or alcohol abuse within 6 months; * Use any other hypoglycemic drugs or weight reducing drugs within 3 months, or use any grug or dietary supplements within 1 weeks prior to screening ; * Underwent surgical procedures within 1 month prior to screening, or planned major surgical procedures during the study period; * Subject who cannot refrain from smoking, eating and/or drinking containing xanthine/caffeine, or strenuous exercise, or others that affect drug absorption, distribution, metabolism and excretion within 2 days before the study drug administration; * With active hepatitis; * Uncontrolled endocrine system diseases (such as hyperthyroidism, hypothyroidism, Cushing syndrome, multiple endocrine neoplasia); * Uncontrolled hypertension with systolic blood pressure (SBP) \> 160mmHg and / or diastolic pressure (DBP) \> 100 mmHg after drug treatment; * History of recurrent severe hypoglycemia; * With severe chronic gastrointestinal disease (e.g., an active ulcer within 6 months) or treatment that may affect drug absorption (e.g., gastrointestinal surgery); * With any cancer (other than skin basal cell carcinoma) that has been treated or untreated within the last 5 years; * History of decompensated heart failure (NYHA grade III and IV), unstable angina, stroke or transient ischemic attack, persistent myocardial infarction, and the clinical significance of arrhythmia (such as frequent contractions), or had coronary artery bypass grafting or percutaneous coronary intervention within 6 months; * History of acute metabolic complications, or proliferative retinopathy or maculopathy which required acute treatment within 6 months; * Severe trauma or severe infection that may affect glycemic control within 1 months before screening; * AST, ALT or TBIL\>1.5×UNL, or Cre\>1.5 mg/dL(male)/1.4 mg/dL(female), or ACR\>300mg/g at screening; * Positive of hepatitis B surface antigen, hepatitis C antibody, HIV antibody or syphilis antibody; * With clinical significance abnormal of ECGs, such as II or III degree atrioventricular block (except right bundle branch block), long QT syndrome or QTc\>500 MS; * Subject was not suitable for the study as determined by the Investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of treatment emergent adverse events | From baseline up to 8 days after last treatment (Day 38) |
| Area under the plasma concentration curve after the first and last multiple oral dose (AUC) | From time 0 to 24 hours for the first dose, and from time 0 to 192 hours after the last dose |
| Peak plasma concentration (Cmax) after the first and last multiple oral dose | From time 0 to 24 hours for the first dose, and from time 0 to 192 hours after the last dose |
| Terminal elimination halflife (t½) for SHR0534 after the last multiple oral dose | From time 0 to 192 hours after the last dose |
| Changes in the concentrations of blood glucose and insulin after multiple oral dose | From baseline up to 24 hours after last treatment (Day 31)] |
Outcome results
None listed